Monday, February 26, 2024
HomeMen HealthAdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001

AdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001

AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the primary patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic Castration-Resistant Prostate Cancer (mCRPC).

“The primary patient dosed with an AdvanCell therapeutic candidate represents a significant milestone for the Company, our scientists, clinical trial sites, and our patients,” said Andrew Adamovich, CEO of AdvanCell. “We imagine that 212Pb is the best radioisotope to comprehend the total therapeutic power of Targeted Alpha Therapy. This promise is strongly supported by preclinical results for 212Pb-ADVC001, which reveal the potential for best-in-class safety and efficacy.”

Patients with metastatic prostate cancer proceed to profit from advances in radiopharmaceutical treatment options. We’re excited to be moving this 212Pb-based therapy forward within the TheraPb clinical study.”

Ken Herrmann, MD, AdvanCell Advisory Board Member and Chair of the Department of Nuclear Medicine, Universitätsklinikum Essen in Germany

Since November 2020, AdvanCell has:

  • Developed the world’s first 212Pb-based Targeted Alpha Therapy to enter clinical trials in metastatic prostate cancer.
  • Invented proprietary platform technology that permits scalable manufacture of 212Pb, the best radioisotope to treat cancer.
  • Signed a letter of intent with a world-class radiopharmaceutical company to collaborate on a worldwide 212Pb radioisotope and radioligand supply chain and drug manufacturing network.
  • Developed a proprietary goal discovery and ligand development program encompassing a strong pipeline of Targeted Alpha Therapies to treat cancer.
  • Raised US $13M from world-class investors including Morningside and awarded $10M in non-dilutive grant funding,
  • Participated within the Cancer Lethality Lead Collaboration, which was awarded $10M from the Prostate Cancer Foundation’s TACTICAL Awards program, in collaboration with the Peter MacCallum Cancer Centre, Uniklinik Essen, University of California Los Angeles, and University of California San Francisco.

Built a 25-person world-class team across Australia and the US and secured a 35,000-square-foot flagship manufacturing facility with plans to expand globally.

- Advertisement -spot_img
- Advertisement -spot_img
Must Read
- Advertisement -spot_img
- Advertisement -spot_img
Related News
- Advertisement -spot_img


Please enter your comment!
Please enter your name here